Literature DB >> 24900076

Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer.

Su Woong Yoo1, Jahae Kim2, Ari Chong2, Seong-Young Kwon1, Jung-Joon Min1, Ho-Chun Song2, Hee-Seung Bom1.   

Abstract

PURPOSE: This study aimed to further stratify prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) by measuring their metabolic tumor volume (MTV) using F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT).
MATERIALS AND METHODS: The subjects of this retrospective study were 57 patients with stage IV NSCLC. MTV, total lesion glycolysis (TLG), and maximum standardized uptake value (SUVmax) were measured on F-18 FDG PET/CT in both the primary lung lesion as well as metastatic lesions in torso. Optimal cutoff values of PET parameters were measured by receiver operating characteristic (ROC) curve analysis. Kaplan-Meier survival curves were used for evaluation of progression-free survival (PFS). The univariate and multivariate Cox proportional hazards models were used to select the significant prognostic factors.
RESULTS: Univariate analysis showed that both MTV and TLG of primary lung lesion (MTV-lung and TLG-lung) were significant factors for prediction of PFS (P < 0.001, P = 0.038, respectively). Patients showing lower values of MTV-lung and TLG-lung than the cutoff values had significantly longer mean PFS than those with higher values. Hazard ratios (95 % confidence interval) of MTV-lung and TLG-lung measured by univariate analysis were 6.4 (2.5-16.3) and 2.4 (1.0-5.5), respectively. Multivariate analysis revealed that MTV-lung was the only significant factor for prediction of prognosis. Hazard ratio was 13.5 (1.6-111.1, P = 0.016).
CONCLUSION: Patients with stage IV NSCLC could be further stratified into subgroups of significantly better and worse prognosis by MTV of primary lung lesion.

Entities:  

Keywords:  F-18 FDG PET/CT; Metabolic tumor volume; Progression-free survival; Stage IV non-small cell lung cancer

Year:  2012        PMID: 24900076      PMCID: PMC4043070          DOI: 10.1007/s13139-012-0165-5

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  29 in total

1.  Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.

Authors:  Jong-Ryool Oh; Ji-Hyoung Seo; Ari Chong; Jung-Joon Min; Ho-Chun Song; Young-Chul Kim; Hee-Seung Bom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-21       Impact factor: 9.236

2.  Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume.

Authors:  Kiyoshi Basaki; Yoshinao Abe; Masahiko Aoki; Hidehiro Kondo; Yoshiomi Hatayama; Shigeyuki Nakaji
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-13       Impact factor: 7.038

3.  Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.

Authors:  Percy Lee; Jose G Bazan; Philip W Lavori; Dilani K Weerasuriya; Andrew Quon; Quynh-Thu Le; Heather A Wakelee; Edward E Graves; Billy W Loo
Journal:  Clin Lung Cancer       Date:  2011-06-24       Impact factor: 4.785

4.  Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.

Authors:  Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-14       Impact factor: 7.038

5.  Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.

Authors:  Johannes B Roedl; Rivka R Colen; Nagaraj S Holalkere; Alan J Fischman; Noah C Choi; Michael A Blake
Journal:  Radiother Oncol       Date:  2008-08-11       Impact factor: 6.280

6.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.

Authors:  Ronald Boellaard; Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

7.  Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.

Authors:  Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim
Journal:  Ann Surg Oncol       Date:  2009-10-14       Impact factor: 5.344

8.  Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data.

Authors:  William N William; Heather Y Lin; J Jack Lee; Scott M Lippman; Jack A Roth; Edward S Kim
Journal:  Chest       Date:  2009-03-24       Impact factor: 9.410

Review 9.  Chemotherapeutic management of stage IV non-small cell lung cancer.

Authors:  Mark A Socinski; David E Morris; Gregory A Masters; Rogerio Lilenbaum
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

10.  Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.

Authors:  Moo-Kon Song; Joo-Seop Chung; Ho-Jin Shin; Sang-Min Lee; Su-Ee Lee; Ho-Sup Lee; Gyeong-Won Lee; Seong-Jang Kim; Seok-Mo Lee; Dong-Seop Chung
Journal:  Ann Hematol       Date:  2011-11-11       Impact factor: 3.673

View more
  24 in total

1.  Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Authors:  Joshua H Finkle; Stephanie Y Jo; Mark K Ferguson; Hai-Yan Liu; Chenpeng Zhang; Xuee Zhu; Cindy Yuan; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-07       Impact factor: 9.236

2.  Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.

Authors:  Yonglin Pu; James X Zhang; Haiyan Liu; Daniel Appelbaum; Jianfeng Meng; Bill C Penney
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-07       Impact factor: 9.236

Review 3.  Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology.

Authors:  Muhammad Kashif Rahim; Sung Eun Kim; Hyeongryul So; Hyung Jun Kim; Gi Jeong Cheon; Eun Seong Lee; Keon Wook Kang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-01-22

4.  Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer.

Authors:  Sae-Ryung Kang; Ho-Chun Song; Byung Hyun Byun; Jong-Ryool Oh; Hyeon-Sik Kim; Sun-Pyo Hong; Seong Young Kwon; Ari Chong; Jahae Kim; Sang-Geon Cho; Hee Jeong Park; Young-Chul Kim; Sung-Ja Ahn; Jung-Joon Min; Hee-Seung Bom
Journal:  Nucl Med Mol Imaging       Date:  2013-09-06

5.  Pretreatment F-18 FDG PET/CT Parameters to Evaluate Progression-Free Survival in Gastric Cancer.

Authors:  Jeonghun Kim; Seok Tae Lim; Chang Ju Na; Yeon-Hee Han; Chan-Young Kim; Hwan-Jeong Jeong; Myung-Hee Sohn
Journal:  Nucl Med Mol Imaging       Date:  2013-11-28

6.  The Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma.

Authors:  Nurşin Agüloğlu; Murat Akyol; Halil Kömek; Nuran Katgı
Journal:  Mol Imaging Radionucl Ther       Date:  2022-06-27

7.  Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.

Authors:  Do-Hoon Kim; Bong-Il Song; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

8.  FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.

Authors:  Hyun Woo Chung; Kye Young Lee; Hee Joung Kim; Wan Seop Kim; Young So
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-06       Impact factor: 4.553

9.  Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.

Authors:  Hyung-Jun Im; Kyoungjune Pak; Gi Jeong Cheon; Keon Wook Kang; Seong-Jang Kim; In-Joo Kim; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-06       Impact factor: 9.236

10.  Differences among [18F]FDG PET-derived parameters in lung cancer produced by three software packages.

Authors:  Agnieszka Bos-Liedke; Paulina Cegla; Krzysztof Matuszewski; Ewelina Konstanty; Adam Piotrowski; Magdalena Gross; Julian Malicki; Maciej Kozak
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.